-Bloomberg   World food prices will drop this year as increase in unemployment in developing and Developed Countries slows growth in demand, the United Nations said.   “We have started to see a decline in food prices,” Jose Graziano da Silva, director general of the UN’s Food and Agriculture Organisation, said at a conference in Hanoi on Thursday. World economic expansion will slow to 3.3% this year from 3.8% in 2011, according to the International...

The government's decision to bust the price as well as monopoly of Bayer's anti-cancer drug, through the process of compulsory licensing now opens up the field for the generic industry to follow suit and could well pave the way for the availability of cheaper drugs for lifestyle diseases.  More generic companies could invoke the compulsory licensing clause of the Indian Patents Act, following Monday's decision to allow Natco Pharma to sell...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...

A tectonic shift in the global climate negotiations got underway with the African group of countries siding with India in demanding that equity and 'common but differentiated responsibilities' be embedded in the talks for a future climate regime. The re-alignments became evident with several key groups of nations submitting their views on how countries should increase their ambition levels for cutting emissions in the coming years. The submissions from Association of Small...

In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...